
Recent large trials, EMPA-KIDNEY and DELIVER, have shown that SGLT-2 inhibitors offer clinical benefits for kidneys and cardiovascular health. This prompted an update to the UK Kidney Association Clinical Practice Guideline. The update covers the use of these inhibitors in various conditions, such as type 1 diabetes, kidney transplants, and heart failure hospital admissions. It also outlines recommendations for future research and implementation. The guidelines include a simplified summary for non-medical individuals, making the information accessible to a broader audience.
Like
Save
Share